Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation

Patrizia Tosi, Carolina Terragna, Nicoletta Testoni, Elena Zamagni, Matteo Renzulli, Paola Tacchetti, Elena Montanari, Giulia Perrone, Michela Ceccolini, Annamaria Brioli, Maria C. Pallotti, Sante Tura, Michele Baccarani, Michele Cavo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

T(4;14) chromosomal abnormality is one of the most adverse prognostic factors predicting for poor outcome in multiple myeloma (MM) patients. It has been recently suggested that bone disease, as evaluated by spinal magnetic resonance imaging (MRI), is relatively infrequent in these patients. In the present study, we aimed at further testing this hypothesis by analyzing the extent of whole bone involvement in patients showing t(4;14) chromosomal translocation as compared with negative patients. For this purpose, 53 consecutive newly diagnosed MM patients (35M, 18F, median age = 55 yr) underwent evaluation of total skeletal X-ray, whole spine MRI, and at the same time, quantification of markers of bone resorption (urinary N-terminal telopeptide, pyridinoline, deoxypyridinoline, serum crosslaps), and bone formation (bone alkaline phosphatase and osteocalcin) was performed. The presence of IgH/MMSET fusion gene as a surrogate marker for t(4;14), was detected in 11 patients (20.7%), whose clinical characteristics were similar to those observed in t(4;14) negative patients. The type of marrow involvement at spinal MRI (diffuse vs. focal vs. negative) was the same in both groups of patients, even though overt vertebral fractures were more frequently found in t(4;14) positive cases (82% vs. 43%, P = 0.05); in line with this finding, skeletal lesions were more common in t(4;14) positive patients (mean skeletal score = 8.54 ± 1.36 SE, as compared with 3.42 ± 0.57 SE in t(4;14) negative cases, P = 0.000). These data were confirmed by the evaluation of serum crosslaps, that were significantly increased in patients with t(4;14) abnormality as compared with negative individuals (10 400 pmol/L ± 2160 SE vs. 5640 pmol/L ± 859 SE P = 0.02) Our results indicate that, at variance to what has been previously reported, bone resorption is more prominent in t(4;14) positive patients.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalEuropean Journal of Haematology
Volume80
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint

Genetic Translocation
Bone Diseases
Multiple Myeloma
glutamyl-lysyl-alanyl-histidyl-aspartyl-glycyl-glycyl-arginine
Magnetic Resonance Imaging
Bone Resorption
Bone and Bones
Gene Fusion
Osteocalcin
Serum
Osteogenesis
Chromosome Aberrations
Alkaline Phosphatase
Spine
Biomarkers
Bone Marrow
X-Rays

Keywords

  • Bone disease
  • Magnetic resonance imaging
  • Multiple myeloma
  • t(4;14)

ASJC Scopus subject areas

  • Hematology

Cite this

Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. / Tosi, Patrizia; Terragna, Carolina; Testoni, Nicoletta; Zamagni, Elena; Renzulli, Matteo; Tacchetti, Paola; Montanari, Elena; Perrone, Giulia; Ceccolini, Michela; Brioli, Annamaria; Pallotti, Maria C.; Tura, Sante; Baccarani, Michele; Cavo, Michele.

In: European Journal of Haematology, Vol. 80, No. 1, 01.2008, p. 31-36.

Research output: Contribution to journalArticle

Tosi, P, Terragna, C, Testoni, N, Zamagni, E, Renzulli, M, Tacchetti, P, Montanari, E, Perrone, G, Ceccolini, M, Brioli, A, Pallotti, MC, Tura, S, Baccarani, M & Cavo, M 2008, 'Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation', European Journal of Haematology, vol. 80, no. 1, pp. 31-36. https://doi.org/10.1111/j.1600-0609.2007.00974.x
Tosi, Patrizia ; Terragna, Carolina ; Testoni, Nicoletta ; Zamagni, Elena ; Renzulli, Matteo ; Tacchetti, Paola ; Montanari, Elena ; Perrone, Giulia ; Ceccolini, Michela ; Brioli, Annamaria ; Pallotti, Maria C. ; Tura, Sante ; Baccarani, Michele ; Cavo, Michele. / Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. In: European Journal of Haematology. 2008 ; Vol. 80, No. 1. pp. 31-36.
@article{8a9769c1b00e4d6b9d57d3748398d132,
title = "Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation",
abstract = "T(4;14) chromosomal abnormality is one of the most adverse prognostic factors predicting for poor outcome in multiple myeloma (MM) patients. It has been recently suggested that bone disease, as evaluated by spinal magnetic resonance imaging (MRI), is relatively infrequent in these patients. In the present study, we aimed at further testing this hypothesis by analyzing the extent of whole bone involvement in patients showing t(4;14) chromosomal translocation as compared with negative patients. For this purpose, 53 consecutive newly diagnosed MM patients (35M, 18F, median age = 55 yr) underwent evaluation of total skeletal X-ray, whole spine MRI, and at the same time, quantification of markers of bone resorption (urinary N-terminal telopeptide, pyridinoline, deoxypyridinoline, serum crosslaps), and bone formation (bone alkaline phosphatase and osteocalcin) was performed. The presence of IgH/MMSET fusion gene as a surrogate marker for t(4;14), was detected in 11 patients (20.7{\%}), whose clinical characteristics were similar to those observed in t(4;14) negative patients. The type of marrow involvement at spinal MRI (diffuse vs. focal vs. negative) was the same in both groups of patients, even though overt vertebral fractures were more frequently found in t(4;14) positive cases (82{\%} vs. 43{\%}, P = 0.05); in line with this finding, skeletal lesions were more common in t(4;14) positive patients (mean skeletal score = 8.54 ± 1.36 SE, as compared with 3.42 ± 0.57 SE in t(4;14) negative cases, P = 0.000). These data were confirmed by the evaluation of serum crosslaps, that were significantly increased in patients with t(4;14) abnormality as compared with negative individuals (10 400 pmol/L ± 2160 SE vs. 5640 pmol/L ± 859 SE P = 0.02) Our results indicate that, at variance to what has been previously reported, bone resorption is more prominent in t(4;14) positive patients.",
keywords = "Bone disease, Magnetic resonance imaging, Multiple myeloma, t(4;14)",
author = "Patrizia Tosi and Carolina Terragna and Nicoletta Testoni and Elena Zamagni and Matteo Renzulli and Paola Tacchetti and Elena Montanari and Giulia Perrone and Michela Ceccolini and Annamaria Brioli and Pallotti, {Maria C.} and Sante Tura and Michele Baccarani and Michele Cavo",
year = "2008",
month = "1",
doi = "10.1111/j.1600-0609.2007.00974.x",
language = "English",
volume = "80",
pages = "31--36",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation

AU - Tosi, Patrizia

AU - Terragna, Carolina

AU - Testoni, Nicoletta

AU - Zamagni, Elena

AU - Renzulli, Matteo

AU - Tacchetti, Paola

AU - Montanari, Elena

AU - Perrone, Giulia

AU - Ceccolini, Michela

AU - Brioli, Annamaria

AU - Pallotti, Maria C.

AU - Tura, Sante

AU - Baccarani, Michele

AU - Cavo, Michele

PY - 2008/1

Y1 - 2008/1

N2 - T(4;14) chromosomal abnormality is one of the most adverse prognostic factors predicting for poor outcome in multiple myeloma (MM) patients. It has been recently suggested that bone disease, as evaluated by spinal magnetic resonance imaging (MRI), is relatively infrequent in these patients. In the present study, we aimed at further testing this hypothesis by analyzing the extent of whole bone involvement in patients showing t(4;14) chromosomal translocation as compared with negative patients. For this purpose, 53 consecutive newly diagnosed MM patients (35M, 18F, median age = 55 yr) underwent evaluation of total skeletal X-ray, whole spine MRI, and at the same time, quantification of markers of bone resorption (urinary N-terminal telopeptide, pyridinoline, deoxypyridinoline, serum crosslaps), and bone formation (bone alkaline phosphatase and osteocalcin) was performed. The presence of IgH/MMSET fusion gene as a surrogate marker for t(4;14), was detected in 11 patients (20.7%), whose clinical characteristics were similar to those observed in t(4;14) negative patients. The type of marrow involvement at spinal MRI (diffuse vs. focal vs. negative) was the same in both groups of patients, even though overt vertebral fractures were more frequently found in t(4;14) positive cases (82% vs. 43%, P = 0.05); in line with this finding, skeletal lesions were more common in t(4;14) positive patients (mean skeletal score = 8.54 ± 1.36 SE, as compared with 3.42 ± 0.57 SE in t(4;14) negative cases, P = 0.000). These data were confirmed by the evaluation of serum crosslaps, that were significantly increased in patients with t(4;14) abnormality as compared with negative individuals (10 400 pmol/L ± 2160 SE vs. 5640 pmol/L ± 859 SE P = 0.02) Our results indicate that, at variance to what has been previously reported, bone resorption is more prominent in t(4;14) positive patients.

AB - T(4;14) chromosomal abnormality is one of the most adverse prognostic factors predicting for poor outcome in multiple myeloma (MM) patients. It has been recently suggested that bone disease, as evaluated by spinal magnetic resonance imaging (MRI), is relatively infrequent in these patients. In the present study, we aimed at further testing this hypothesis by analyzing the extent of whole bone involvement in patients showing t(4;14) chromosomal translocation as compared with negative patients. For this purpose, 53 consecutive newly diagnosed MM patients (35M, 18F, median age = 55 yr) underwent evaluation of total skeletal X-ray, whole spine MRI, and at the same time, quantification of markers of bone resorption (urinary N-terminal telopeptide, pyridinoline, deoxypyridinoline, serum crosslaps), and bone formation (bone alkaline phosphatase and osteocalcin) was performed. The presence of IgH/MMSET fusion gene as a surrogate marker for t(4;14), was detected in 11 patients (20.7%), whose clinical characteristics were similar to those observed in t(4;14) negative patients. The type of marrow involvement at spinal MRI (diffuse vs. focal vs. negative) was the same in both groups of patients, even though overt vertebral fractures were more frequently found in t(4;14) positive cases (82% vs. 43%, P = 0.05); in line with this finding, skeletal lesions were more common in t(4;14) positive patients (mean skeletal score = 8.54 ± 1.36 SE, as compared with 3.42 ± 0.57 SE in t(4;14) negative cases, P = 0.000). These data were confirmed by the evaluation of serum crosslaps, that were significantly increased in patients with t(4;14) abnormality as compared with negative individuals (10 400 pmol/L ± 2160 SE vs. 5640 pmol/L ± 859 SE P = 0.02) Our results indicate that, at variance to what has been previously reported, bone resorption is more prominent in t(4;14) positive patients.

KW - Bone disease

KW - Magnetic resonance imaging

KW - Multiple myeloma

KW - t(4;14)

UR - http://www.scopus.com/inward/record.url?scp=37249023709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249023709&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2007.00974.x

DO - 10.1111/j.1600-0609.2007.00974.x

M3 - Article

VL - 80

SP - 31

EP - 36

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 1

ER -